Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Terri L. Parker, MD, Adam Rosenthal, MS, Vaishali Sanchorawala, MD, Heather J Landau, MD, Erica Campagnaro, MD, Prashant Kapoor, MD, Natalia Neparidze, MD, Patrick Hagen, MD, Shayna Sarosiek, MD, Emma C. Scott, MD, Antje Hoering, PhD, Brian G.M. Durie, MD, Saad Z. Usmani, MDMBBS,MBA, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-143180

Published: 2020

Journal Articles

Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Amrita Krishnan, MD, Antje Hoering, PhD, Parameswaran Hari, MD MRCP, Rachael Sexton, PhD, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142913

Published: 2020

Journal Articles

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Frits van Rhee, MD PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Jeffery R. Sawyer, Adam Rosenthal, MS, Doug Steward, Phil Farmer, Robert Smith, Milan Bimali, PhD, Mariam M. Boota, MD, Clyde Bailey, Brian A Walker, PhD, Antje Hoering, PhD, Gareth Morgan, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD

Blood (2019) 134 (Supplement_1): 4569.

https://doi.org/10.1182/blood-2019-131887

Published: 2019

Journal Articles

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Guido J. Tricot, MD PhD, Doug Steward, Susan Panozzo, Jeffery R. Sawyer, Brian A Walker, PhD, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Katherine K Nishimura, Bart Barlogie, MD PhD

Blood (2019) 134 (Supplement_1): 3309.

https://doi.org/10.1182/blood-2019-131870

Published: 2019

Journal Articles

High Levels of APOBEC3B Gene Expression Contribute to Poor Prognosis in Multiple Myeloma Patients

Valeriy V Lyzogubov, MD PhD, Pingping Qu, Cody Ashby, PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Faith E. Davies, MD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 3897.

https://doi.org/10.1182/blood-2018-99-117067

Published: 2018

Journal Articles

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

Tarun K. Garg, PhD, Katie Stone, BS, Hongwei Wang, MS, Antje Hoering, PhD, Brian A Walker, PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Faith E. Davies, MD, Gareth Morgan, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 4468.

https://doi.org/10.1182/blood-2018-99-119692

Published: 2018

Journal Articles

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Joshua Epstein, DSc, Maurizio Zangari, MD, Pingping Qu, Antje Hoering, PhD, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Faith E. Davies, MD, Gareth Morgan, MD, Shmuel Yaccoby, PhD

Blood (2018) 132 (Supplement 1): 4448.

https://doi.org/10.1182/blood-2018-99-115244

Published: 2018

Journal Articles

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Blood (2018) 132 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2018-99-119113

Published: 2018

Journal Articles

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Cody Ashby, PhD, Eileen Boyle, Ruslana G. Tytarenko, MS, Hongwei Wang, MS, Adam Rosenthal, MS, Purvi Patel, Yan Wang, Shayu Deshpande, Maria Ortiz, Erin Flynt, Antje Hoering, PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Bart Barlogie, MD PhD, Anjan Thakurta, PhD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 110.

https://doi.org/10.1182/blood-2018-99-113045

Published: 2018

Journal Articles

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Brian GM Durie, MD, Antje Hoering, PhD, Rachael Sexton, PhD, Muneer H. Abidi, MD, Joshua Epstein, DSc, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J. Reu, MD, Christopher M. Reynolds, MD, Robert Z. Orlowski, MD PhD, Bart Barlogie, MD PhD

Blood (2018) 132 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2018-99-117003

Published: 2018

Journal Articles

African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma: Results of a Prospective Study SWOG S0120

Madhav V Dhodapkar, MD, Rachael Sexton, PhD, Antje Hoering, PhD, Bart Barlogie, MD PhD, Robert Z. Orlowski, MD PhD

Blood (2018) 132 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2018-99-119634

Published: 2018

Journal Articles

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

Blood (2018) 132 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2018-99-113169

Published: 2018

Journal Articles

Sequential Improvements in the Outcome of Autologous Stem Cell Transplantation for Multiple Myeloma over Time

Katherine K Nishimura, Brian A Walker, PhD, Adam Rosenthal, MS, Faith E. Davies, MD, Bart Barlogie, MD PhD, Frits van Rhee, MD PhD, Gareth Morgan, MD, Antje Hoering, PhD

Blood (2018) 132 (Supplement 1): 3168.

https://doi.org/10.1182/blood-2018-99-118605

Published: 2018

Journal Articles

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

Blood (2016) 128 (22): 906.

https://doi.org/10.1182/blood.V128.22.906.906

Published: 2016

Journal Articles

Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials

Sikander Ailawadhi, MD, Susanna Joan Jacobus, MSc, Rachael Sexton, MS, A. Keith Stewart, MD, Angela Dispenzieri, MD, Mohamad A. Hussein, Jeffrey Zonder, MD, John Crowley, PhD, Antje Hoering, PhD, Bart Barlogie, MD PhD, Robert Z. Orlowski, PhD, MD, S. Vincent Rajkumar, MD

Blood (2016) 128 (22): 1192.

https://doi.org/10.1182/blood.V128.22.1192.1192

Published: 2016

Journal Articles

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Blood (2016) 128 (22): 902.

https://doi.org/10.1182/blood.V128.22.902.902

Published: 2016

Journal Articles

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Blood (2016) 128 (22): 2064.

https://doi.org/10.1182/blood.V128.22.2064.2064

Published: 2016

Journal Articles

Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma

Shmuel Yaccoby, PhD, Pingping Qu, PhD, Syed Mehdi, Antje Hoering, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 2065.

https://doi.org/10.1182/blood.V128.22.2065.2065

Published: 2016

Journal Articles

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Pingping Qu, PhD, Frits van Rhee, MD PhD, Yogesh Jethava, MB, MRCP, MD FRCPath, Caleb K. Stein, MS, Emily Hansen, Alan Mitchell, Maurizio Zangari, MD, Christoph Heuck, MD, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Faith E Davies, MD, Antje Hoering, PhD, John Crowley, PhD, Niels Weinhold, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1806.

https://doi.org/10.1182/blood.V126.23.1806.1806

Published: 2015

Journal Articles

Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines

Shmuel Yaccoby, Joshua Epstein, DSc, Pingping Qu, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Faith E Davies, MD, Alan Mitchell, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1808.

https://doi.org/10.1182/blood.V126.23.1808.1808

Published: 2015

NARROW

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

High Levels of APOBEC3B Gene Expression Contribute to Poor Prognosis in Multiple Myeloma Patients

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma: Results of a Prospective Study SWOG S0120

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

Sequential Improvements in the Outcome of Autologous Stem Cell Transplantation for Multiple Myeloma over Time

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only